Hypoxia provokes base excision repair changes and a repair-deficient, mutator phenotype in colorectal cancer cells.

Molecular cancer research : MCR (2014-07-18)
Norman Chan, Mohsin Ali, Gordon P McCallum, Ramya Kumareswaran, Marianne Koritzinsky, Bradly G Wouters, Peter G Wells, Steven Gallinger, Robert G Bristow
ABSTRAKT

Regions of acute and chronic hypoxia exist within solid tumors and can lead to increased rates of mutagenesis and/or altered DNA damage and repair protein expression. Base excision repair (BER) is responsible for resolving small, non-helix-distorting lesions from the genome that potentially cause mutations by mispairing or promoting DNA breaks during replication. Germline and somatic mutations in BER genes, such as MutY Homolog (MUTYH/MYH) and DNA-directed polymerase (POLB), are associated with increased risk of colorectal cancer. However, very little is known about the expression and function of BER proteins under hypoxic stress. Using conditions of chronic hypoxia, decreased expression of BER proteins was observed because of a mechanism involving suppressed BER protein synthesis in multiple colorectal cancer cell lines. Functional BER was impaired as determined by MYH- and 8-oxoguanine (OGG1)-specific glycosylase assays. A formamidopyrimidine-DNA glycosylase (Fpg) Comet assay revealed elevated residual DNA base damage in hypoxic cells 24 hours after H2O2 treatment as compared with normoxic controls. Similarly, high-performance liquid chromatography analysis demonstrated that 8-oxo-2'-deoxyguanosine lesions were elevated in hypoxic cells 3 and 24 hours after potassium bromate (KBrO3) treatment when compared with aerobic cells. Correspondingly, decreased clonogenic survival was observed following exposure to the DNA base damaging agents H2O2 and MMS, but not to the microtubule interfering agent paclitaxel. Thus, a persistent downregulation of BER components by the microenvironment modifies and facilitates a mutator phenotype, driving genetic instability and cancer progression. Aberrant BER is a contributing factor for the observed genetic instability in hypoxic tumor cells.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
MISSION® esiRNA, targeting human POLG2
Sigma-Aldrich
MISSION® esiRNA, targeting human MUTYH
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Polb
Sigma-Aldrich
MISSION® esiRNA, targeting human POLB
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Mutyh
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Polg2

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.